Trial · NCT07500844
Decontamination Methods in the Treatment of Peri-implantitis
NCT07500844, Not applicable, Completed, Research Centre for Medical Genetics, Russian Federation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Decontamination Methods in the Treatment of Peri-implantitis. Trials, record NCT07500844. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07500844
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Decontamination Methods in the Treatment of Peri-implantitis
- NCT number
- NCT07500844
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 64 participants, actual
- Lead sponsor
- Research Centre for Medical Genetics, Russian Federation
- Conditions
- Peri-implantitis
- Interventions
- Miramistin, Sodium Bicarbonate Powder, Chlorhexidine, Erythritol Powder, Octenisept, Glycine Powder
- First posted
- 2026-03-30
- Last updated
- 2026-04-03
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Probing Depth | Baseline, 1 month, and 2.5 months after start of treatment | Probing depth measured in millimeters using a graduated periodontal probe (UNC-15) at six sites per implant: mesiobuccal, buccal, distobuccal, mesiolingual, lingual, and distolingual. The mean probing depth per implant is calculated. A reduction in probing depth indicates treatment success. |
| Primary | Bleeding on Probing | Baseline, 1 month, and 2.5 months after start of treatment | Presence or absence of bleeding within 30 seconds after gentle probing at six sites per implant. The percentage of sites showing bleeding per implant is recorded. A decrease in bleeding on probing indicates improvement in peri-implant soft tissue health. |
| Secondary | Plaque Index | Baseline, 1 month, and 2.5 months after start of treatment | Plaque accumulation assessed using the Silness-Löe Plaque Index (0-3 scale) at six sites per implant. Mean PLI is calculated per implant. |
| Secondary | Gingival Index | Baseline, 1 month, and 2.5 months after start of treatment | Gingival inflammation assessed using the Löe-Silness Gingival Index (0-3 scale) at six sites per implant. Mean GI is calculated per implant. |
| Secondary | Radiographic Bone Loss | Baseline and 2.5 months after start of treatment | Vertical bone loss measured in millimeters from a fixed reference point (e.g., implant shoulder) to the most coronal bone-to-implant contact, assessed on periapical radiographs and cone-beam computed tomography (CBCT). |
| Secondary | Need for Surgical Intervention | From start of treatment through 2.5 months | Number and severity of adverse events related to the treatment, including post-operative pain, soft tissue irritation, allergic reactions, or any unexpected events. |
| Secondary | Suppuration | Baseline, 1 month, and 2.5 months after start of treatment | Presence or absence of suppuration (purulent exudate) after gentle probing. Reported as the percentage of sites with suppuration per implant. |
| Other | Safety / Adverse Events | From start of treatment through 2.5 months | Number and severity of adverse events related to the treatment, including post-operative pain, soft tissue irritation, allergic reactions, or any unexpected events. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07500844
GET https://conductscience.org/api/trials/v1/NCT07500844/registered